Shopping Cart
Remove All
Your shopping cart is currently empty
Emicizumab
😃Good
Catalog No. T77457Cas No. 1610943-06-0
Alias RO 5534262, ACE 910
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.
Emicizumab
😃Good
Catalog No. T77457Alias RO 5534262, ACE 910Cas No. 1610943-06-0
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,390 | In Stock | In Stock | |
| 5 mg | $2,910 | - | In Stock | |
| 10 mg | $3,930 | - | In Stock | |
| 25 mg | $5,850 | - | In Stock | |
| 50 mg | $7,840 | - | In Stock | |
| 100 mg | $10,600 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.1% (SDS-PAGE); 95.9% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A. |
| In vivo | Emicizumab (1.5-10 mg/kg; i.v.; 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia type A bleeding model with an FVIII equivalent of 9 U/dL.[1]
Emicizumab (3 mg/kg; intravenously) provides additional hemostatic activity when combined with low-dose FVIII (10 U/dL).[1] |
| Synonyms | RO 5534262, ACE 910 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | F9/Factor IX |
| Molecular Weight | 145.14 kDa |
| Cas No. | 1610943-06-0 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Emicizumab | purchase Emicizumab | Emicizumab cost | order Emicizumab | Emicizumab chemical structure | Emicizumab in vivo | Emicizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.